Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01732926
Title Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gilead Sciences
Indications

follicular lymphoma

lymphoplasmacytic lymphoma

marginal zone B-cell lymphoma

non-Hodgkin lymphoma

chronic lymphocytic leukemia

Therapies

Idelalisib

Bendamustine + Rituximab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.